(Stroke. 2003;34:22.)
© 2003 American Heart Association, Inc.
Original Contributions |
From the Division Public Health and Primary Health Care, Institute of Health Sciences (R.R.H., H.A.W.N.), and Oxford Lipid Metabolism Group, Nuffield Department of Medicine (F.K.), University of Oxford, Oxford, UK; Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK (M.H.H.); and Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free and University College Medical School (S.E.H.).
Correspondence to Dr H.A.W. Neil, Division of Public Health and Primary Health Care, Institute of Health Sciences, University of Oxford, Old Road, Headington, Oxford, UK OX3 7LF. E-mail andrew.neil{at}wolfson.ox.ac.uk
Background and Purpose Although it is recognized that in heterozygous familial hypercholesterolemia, large extracranial carotid vessels are affected by atherosclerosis, the risk of fatal stroke after treatment with cholesterol-lowering therapy remains uncertain. The goal of this study was to determine the risk of fatal stroke in patients with treated familial hypercholesterolemia.
Methods A cohort of 1405 men and 1466 women with definite or possible heterozygous familial hypercholesterolemia was recruited from 21 outpatient lipid clinics in the United Kingdom. Patients were followed up prospectively from 1980 to 1998 for 22 992 person-years for a median duration of 7.9 years (interquartile range, 4.9 to 12.0 years). The mortality rate was calculated, and the standardized mortality ratio for men and women 20 to 79 years of age was derived from the ratio of the observed deaths to the number expected in the general population of England and Wales (standardized mortality ratio=100 for the standard population).
Results A total of 169 deaths occurred; 9 (5.3%) were a result of stroke. The mortality rate from stroke was 0.39 per 1000 person-years (95% confidence interval, 0.18 to 0.74), and the standardized mortality ratio for fatal stroke was nonsignificantly lower than in the general population (79; 95% CI, 36 to 150).
Conclusions The results suggest that patients with treated familial hypercholesterolemia are not at increased risk of fatal stroke. However, the possibility cannot be excluded that untreated individuals are at increased risk, which would be consistent with the evidence that familial hypercholesterolemia is a panvascular disease.
This article has been cited by other articles:
![]() |
S. Soljanlahti, T. Autti, K. Lauerma, R. Raininko, P. Keto, H. Turtola, and A. F. Vuorio Familial Hypercholesterolemia Patients Treated With Statins at No Increased Risk for Intracranial Vascular Lesions Despite Increased Cholesterol Burden and Extracranial Atherosclerosis Stroke, July 1, 2005; 36(7): 1572 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Austin, C. M. Hutter, R. L. Zimmern, and S. E. Humphries Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review Am. J. Epidemiol., September 1, 2004; 160(5): 421 - 429. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Hutter, M. A. Austin, and S. E. Humphries Familial Hypercholesterolemia, Peripheral Arterial Disease, and Stroke: A HuGE Minireview Am. J. Epidemiol., September 1, 2004; 160(5): 430 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.R. Huxley, M.H. Hawkins, S.E. Humphries, F. Karpe, H.A.W. Neil, and J. F. Meschia Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study * Editorial Comment Stroke, January 1, 2003; 34(1): 22 - 25. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |